Sage Therapeutics 株価情報 (NASDAQ: SAGE)

最新ニュース Sage Therapeutics (NASDAQ:SAGE) 株価情報

SAGE THERAPEUTICS INC

Sage Therapeutics

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Sage Therapeutics Inc

SAGEN MI CDA INC PFD A by SAGEN MI CDA INC.

Sage Gold Inc

Sage Group (The) PLC

SAGE GROUP UNSP/ADR by Sage Group plc (The)

Sage Potash Corp

Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Hold to Hold.

News

Reiteration

Analyst Ratings

SAGE

Needham Reiterates Hold on Sage Therapeuticsto Hold

Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.99) by 2.02 percent. This is a 43.89 percent increase over losses of $(1.80) per share from the same period last year. The company reported quarterly sales of $14.06 million which met the analyst consensus estimate. This is a 77.97 percent increase over sales of $7.90 million the same period last year.

Earnings

Earnings Misses

Sage Therapeutics Q1 EPS $(1.01) Misses $(0.99) Estimate, Sales $14.06M Inline

ACGL

AEYE

AMSF

APAM

ARCB

ARCC

ASTE

ASTL

ATRC

BBIO

BBVA

BGFV

BKNG

BRSP

CECO

CHCT

CLVT

CSGP

CVLT

DHIL

ENSG

ENVA

ESRT

ETWO

EXLS

FELE

FFIC

FIBK

FICO

FOUR

FRSH

FRST

FSLR

FYBR

HLMN

HOUS

HRZN

HSBC

HURN

ILPT

INCY

INTZ

JAKK

JBGS

JBLU

KNSA

LFUS

LGIH

Laboratory Corporation Of America Holdings

LOGI

LXFR

Earnings Scheduled For April 29, 2025

Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Sage Therapeutics to report an earnings per share (EPS) of $-0.99.
The market awaits Sage Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
The company's EPS missed by $0.20 in the last quarter, leading to a 0.42% drop in the share price on the following day.
Here's a look at Sage Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.36</td>
<td>-1.53</td>
<td>-1.66</td>
<td>-1.65</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.56</td>
<td>-1.53</td>
<td>-1.70</td>
<td>-1.80</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>-24.0%</td>
<td>-11.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745866969_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Sage Therapeutics were trading at $7.79 as of April 25. Over the last 52-week period, shares are down 44.51%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analysts' Perspectives on Sage Therapeutics</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Sage Therapeutics.
A total of 4 analyst ratings have been received for Sage Therapeutics, with the consensus rating being Neutral. The average one-year price target stands at $9.5, suggesting a potential 21.95% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Regenxbio, Precigen and MeiraGTx Hldgs, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Regenxbio, with an average 1-year price target of $32.0, suggesting a potential 310.78% upside.</li>
<li>Analysts currently favor an Buy trajectory for Precigen, with an average 1-year price target of $6.0, suggesting a potential 22.98% downside.</li>
<li>Analysts currently favor an Buy trajectory for MeiraGTx Hldgs, with an average 1-year price target of $24.5, suggesting a potential 214.51% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
Within the peer analysis summary, vital metrics for Regenxbio, Precigen and MeiraGTx Hldgs are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sage Therapeutics</td>
<td>Neutral</td>
<td>-83.56%</td>
<td>$11.33M</td>
<td>-18.84%</td>
</tr>
<tr>
<td>Regenxbio</td>
<td>Buy</td>
<td>-4.50%</td>
<td>$14.90M</td>
<td>-18.25%</td>
</tr>
<tr>
<td>Precigen</td>
<td>Buy</td>
<td>-3.09%</td>
<td>$21K</td>
<td>-42.02%</td>
</tr>
<tr>
<td>MeiraGTx Hldgs</td>
<td>Buy</td>
<td>948.53%</td>
<td>$9.58M</td>
<td>-48.18%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Sage Therapeutics ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages indicating a decline. However, it ranks at the top for Return on Equity, showing a positive trend. Overall, Sage Therapeutics is positioned in the middle compared to its peers based on the provided metrics.
<h3>Delving into Sage Therapeutics's Background</h3>
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
<h3>Sage Therapeutics: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Sage Therapeutics faced challenges, resulting in a decline of approximately -83.56% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Sage Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -747.33%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -18.84%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Sage Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -16.38%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.03, Sage Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/SAGE/earnings">To track all earnings releases for Sage Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What to Expect from Sage Therapeutics's Earnings

In the last three months, 4 analysts have published ratings on Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $9.5, a high estimate of $12.00, and a low estimate of $6.00. Highlighting a 11.63% decrease, the current average has fallen from the previous average price target of $10.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1745607631_0_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Sage Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;George Farmer &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Outperform&#x7C; $12.00&#x7C;$14.00 &#x7C; 
&#x7C;Laura Chico &#x7C;Wedbush &#x7C;Maintains &#x7C;Neutral &#x7C; $6.00&#x7C;$6.00 &#x7C; 
&#x7C;Sumant Kulkarni &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $8.00&#x7C;$9.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Lowers &#x7C;Neutral &#x7C; $12.00&#x7C;$14.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sage Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Sage Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Sage Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Sage Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SAGE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sage Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Sage Therapeutics Better</h2>
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
<h3>Financial Insights: Sage Therapeutics</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Sage Therapeutics's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -83.56%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Sage Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -747.33%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Sage Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -18.84%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -16.38%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.03, Sage Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Sage Therapeutics Through The Eyes Of 4 Analysts

U.S. stock futures were swinging between gains and losses on Thursday after snapping a three-day winning streak on Wednesday. Futures of major benchmark indices were mixed in premarket trading.
Aiming to boost U.S. manufacturing and reduce reliance on global suppliers, new auto tariffs were introduced on Wednesday, which will go into effect from April 3.
Projected to generate $100 billion annually, President Donald Trump stated the policy &#8220;will continue to spur growth.&#8221; It&#8217;s noted that within the <a href="https://www.benzinga.com/25/03/44506345/trump-imposes-25-tariffs-on-auto-imports-says-this-will-continue-to-spur-growth-canada-eu-slam-the-move">USMCA agreement</a>, the 25% tariff only impacts the non-U.S. content of auto goods from Canada and Mexico. 
With the 10-year Treasury yield at 4.38% and the 2-year at 4.02%, the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a> shows markets pricing in a 90.4% likelihood of the Federal Reserve maintaining current interest rates through its May meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.01%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.07%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.17%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.31%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were mixed in premarket on Thursday. The SPY was up 0.10% to $569.18, while the QQQ declined 0.025% to $484.26, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Most sectors on the S&amp;P 500 closed lower on Wednesday, with Consumer Discretionary, Communication Services, and Information Technology stocks recording the biggest losses.
However, Utilities and Consumer Staples bucked the overall market trend, closing the session higher.
Dragging the tech-heavy index Nasdaq down were major stocks like Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), which fell over 2%, while Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ: GOOGL declined more than 3%.
On the economic data front, U.S. new orders for manufactured durable goods rose 0.9% month over month in February to $289.3 billion.
The Dow Jones index fell 133 points or 0.31% on Wednesday to 42,454.79, whereas the S&amp;P 500 index was down 1.12% at 5,712.20. Nasdaq Composite notched a 2.04% drop to end at 17,899.02, and the small-cap gauge, Russell 2000, declined 1.03% to 2,073.83.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-2.04%</td>
<td>17,899.02</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.12%</td>
<td>5,712.20</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.31%</td>
<td>42,454.79</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.03%</td>
<td>2,073.83</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
As Trump introduced auto tariffs and the date for implementing &#8220;reciprocal tariffs&#8221; near, Louis Navellier, the founder and CIO of Navellier &amp; Associates, said, &#8220;Expect volatility. Buckle up.&#8221;
&#8220;We&#8217;re a week away from Trump&#8217;s &#8216;Liberation Day,&#8217; when he plans to implement reciprocal tariffs, focusing on trading partners with significant trade imbalances with the U.S. It&#8217;s a risk factor that investors have never faced and may explain why the VIX is starting to rise again after falling since the March 10th high,&#8221; he added.
Scott Wren, senior global market strategist at Wells Fargo, believes that although tariffs come with anticipated economic costs, actions by both companies and consumers can substantially lessen their negative impact.
&#8220;Let&#8217;s be clear: We expect tariffs to have some economic cost," Wren acknowledged. He pointed out that price hikes implemented by some U.S. firms due to tariffs have often been lower than the tariff percentage itself, noting that strong corporate profitability provides "some room to absorb a portion of the price increases."
Steps toward mitigation are already being taken, Wren indicated. "Keep in mind that some companies have been diversifying supply chains since the early days of the pandemic or even prior to that," he elaborated.
Consumer behavior also factors in. "Consumers can also blunt some of the effect of potential tariffs… for many products, there are substitution possibilities," Wren remarked, mentioning shifts toward domestic products as an example. He assesses that "these reactions will blunt and dilute much of the negative tariff impact."
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a> 
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Thursday:
<ul>
<li>Initial jobless claims data, second revision of GDP, advanced U.S. trade balance in goods, and advanced wholesale inventories data are to be released at 8:30 a.m. ET.</li>
</ul>
<ul>
<li>Pending home sales data is set to be released at 10 a.m. ET.</li>
</ul>
<ul>
<li>Richmond Fed President Tom Barkin is set to speak at 4:30 p.m.</li>
</ul>
Stocks In Focus:
<ul>
<li>TD Synnex Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) was up 0.27% in premarket on Thursday ahead of its earnings before the opening bell. Analysts expect quarterly earnings of $2.91 per share on revenue of $14.79 billion.</li>
</ul>
<ul>
<li>Winnebago Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) was down 0.029% as Wall Street expects it to report earnings of 13 cents per share on revenue of $616.66 million before the opening bell.</li>
</ul>
<ul>
<li>Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) slipped 0.38% ahead of its earnings after the closing bell. Analysts expect quarterly earnings of $5.85 per share on revenue of $3.57 billion.</li>
</ul>
<ul>
<li>Steelcase Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) jumped 11.79% after reporting better-than-expected fourth-quarter financial results and issuing first-quarter guidance above estimates.</li>
</ul>
<ul>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) dropped 6.42% after it announced the issuance of $1.3 billion worth of its 0.00% convertible senior notes due 2030 in a private offering to institutional investors to acquire Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).</li>
</ul>
<ul>
<li>American Rebel Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) slumped 24.63% as the company announced that it will implement a 1-for-25 reverse stock split on March 31, 2025, reducing shares from ~10.6 million to ~423 thousand.</li>
</ul>
<ul>
<li>SAGE Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) declined 2.91% after it announced that Jacqui Cartin will replace Jonathan Howell as CFO in January 2026.</li>
</ul>
<ul>
<li>Aura Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) rose 9.68% as it highlighted progress with Bel-Sar. Bel-sar showed positive Phase 1 NMIBC data at the EAU Congress.</li>
</ul>
<ul>
<li>Soleno Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) surged 36.82% after it received FDA approval for VYKAT XR (diazoxide choline), the first treatment for hyperphagia in Prader-Willi syndrome for patients aged four and older.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.39% to hover around $69.38 per barrel.
Gold Spot US Dollar advanced 0.59% to hover around $3,036.97 per ounce. Its previous record high stood at $3,057.51 per ounce.
Asian markets closed on a mixed note on Thursday. China&#8217;s CSI 300, India's S&amp;P BSE Sensex, and Hong Kong's Hang Seng index rose in trade. Whereas, South Korea's Kospi, Japan's Nikkei 225, and Australia's ASX 200 index declined. European markets were lower in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44508744/donald-trump-reacts-to-selloff-following-auto-tariffs-that-can-take-care-of-itself-in-one-day-two-days-or-one-week">Trump Reacts To Selloff Following Auto Tariffs: &#8216;That Can Take Care Of Itself In One Day, Two Days, Or One Week&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Analyst Color

Asia

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings Beats

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

Regulations

Bonds

Broad U.S. Equity ETFs

Guidance

Eurozone

Futures

Commodities

Forex

Treasuries

Economics

Federal Reserve

Pre-Market Outlook

Markets

ETFs

General

$BTC

AMZN

AREB

AURA

GOOG

LULU

SLNO

US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert

U.S. stock futures were mixed this morning, with the S&amp;P 500 futures gaining around 0.1% on Tuesday.
Shares of KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) fell sharply in today's pre-market trading as the company reported weaker-than-expected first-quarter results after the <a href="https://in.benzinga.com/news/earnings/25/03/44465789/kb-home-q1-earnings-revenue-miss-eps-miss-demand-more-muted-than-expected-buyers-responding-favorably-to-value-pivot-and-more">closing bell on Monday</a>.
KB Home reported first-quarter revenue of $1.39 billion, missing analyst estimates of $1.50 billion. The U.S. homebuilder reported first-quarter earnings of $1.49 per share, missing analyst estimates of $1.59 per share, according to Benzinga Pro.
KB Home said it expects full-year 2025 housing revenue to be in the range of $6.6 billion to $7 billion. The company anticipates 2025 average selling prices of $480,000 to $495,000..
KB Home shares dipped 8% to $56.85 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares dipped 12.3% to $7.20 in pre-market trading.</li>
<li>UniFirst Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) shares declined 10.2% to $177.48 in pre-market trading after Cintas announced an end to discussions regarding its acquisition proposal of the company.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares fell 9.1% to $37.26 in pre-market trading.</li>
<li>Lotus Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOT#NASDAQ">LOT</a>) fell 8.7% to $2.00 in pre-market trading.</li>
<li>Oklo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NASDAQ">OKLO</a>) declined 7.4% to $28.61 in pre-market trading after the company reported a year-over-year decrease in FY24 EPS results.</li>
<li>Metsera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) fell 6.8% to $28.02 in pre-market trading.</li>
<li>China Yuchai International Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYD#NYSE">CYD</a>) fell 6.8% to $17.80 in pre-market trading.</li>
<li>Qifu Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) slipped 3.9% to $42.74 in pre-market trading as the company announced a proposed offering of $600 million cash-par settled convertible senior notes.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/03/44457888/top-2-financial-stocks-that-may-fall-off-a-cliff-in-march">Top 2 Financial Stocks That May Fall Off A Cliff In March</a></li>
</ul>
Image: Shutterstock

Movers

Trading Ideas

MTSR

OKLO

QFIN

KB Home Posts Downbeat Results, Joins UniFirst, Oklo And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Shares of Power Solutions International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIX#NASDAQ">PSIX</a>) rose sharply in today's pre-market trading after <a href="https://www.benzinga.com/quote/PSIX/earnings">reporting fourth-quarter results.</a>
Power Solutions posted fourth-quarter earnings of $1.01 per share, up from 36 cents per share in the year-ago period.
Power Solutions International shares jumped 9.8% to $32.75 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Tenon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) rose 91.2% to $1.87 in pre-market trading after the company announced the FDA clearance of Catamaran(R) SI Joint Fusion System for new indication to augment spinal fusion.</li>
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) gained 46.1% to $0.3736 in pre-market trading after falling 11% on Monday.</li>
<li>Toppoint Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOPP#NYSE">TOPP</a>) gained 27.2% to $1.92 in pre-market trading after declining around 10% on Monday.</li>
<li>Star Fashion Culture Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STFS#NASDAQ">STFS</a>) gained 24.2% to $1.33 in pre-market trading after gaining 14% on Monday.</li>
<li>Know Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNW#NYSE">KNW</a>) rose 21.9% to $1.28 in pre-market trading after dipping over 13% on Monday.</li>
<li>System1, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) gained 20.3% to $0.5174 in pre-market trading after tumbling 14% on Monday.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) gained 17.4% to $1.62 in pre-market after the company secured a new $41 million funding commitment to advance Faraday X and AI strategic upgrades.</li>
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) rose 15.3% to $1.66 in pre-market trading after falling over 8% on Monday.</li>
<li>BitFuFu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) gained 9.2% to $4.87 in pre-market trading following full year 2024 results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Integrated Media Technology Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMTE#NASDAQ">IMTE</a>) fell 30% to $1.47 in pre-market trading after jumping 197% on Monday.</li>
<li>Tungray Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRSG#NASDAQ">TRSG</a>) shares fell 24.6% to $1.54 in pre-market trading after jumping 86% on Monday.</li>
<li>Mural Oncology plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) shares tumbled 22.5% to $2.97 in pre-market trading after the company issued an update on Phase 3 ARTISTRY-7 trial of Nemvaleukin in combination with KEYTRUDA&#xAE; (pembrolizumab) in patients with platinum-resistant ovarian cancer.</li>
<li>VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>) declined 19.8% to $2.58 in pre-market trading. VivoPower International shares jumped 150% on Monday after the company announced it received a non-binding takeover proposal from Energi Holdings.</li>
<li>Prairie Operating Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROP#NASDAQ">PROP</a>) fell 19.5% to $4.72 in pre-market trading after the company announced the pricing of common stock offering.</li>
<li>TEN Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHLD#NASDAQ">XHLD</a>) dipped 18.1% to $1.76 in pre-market trading. TEN Holdings shares surged 54% on Monday after the company announced it will add conersational AI solutions to its portfolio.</li>
<li>Digital Ally, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) shares dipped 15.7% to $0.0462 in pre-market trading after tumbling 18% on Monday.</li>
<li>Atomera Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOM#NASDAQ">ATOM</a>) fell 14.5% to $4.93 in today's pre-market trading.</li>
<li>Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) fell 12.3% to $7.20 in pre-market trading.</li>
<li>Orchestra BioMed Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) shares fell 9.7% to $4.13 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/03/44457888/top-2-financial-stocks-that-may-fall-off-a-cliff-in-march">Top 2 Financial Stocks That May Fall Off A Cliff In March</a></li>
</ul>
Image: Shutterstock

ATOM

DGLY

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

FUFU

IMTE

MULN

MURA

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

PROP

PSIX

STFS

TNON

TOPP

TRSG

VVPR

XHLD

Why Power Solutions International Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket

Scotiabank analyst George Farmer maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Sector Outperform and lowers the price target from $14 to $12.

Price Target

Scotiabank Maintains Sector Outperform on Sage Therapeutics, Lowers Price Target to $12

Wedbush analyst Laura Chico reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and maintains $6 price target.

Wedbush Reiterates Neutral on Sage Therapeutics, Maintains $6 Price Target

Throughout the last three months, 7 analysts have evaluated Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.86, a high estimate of $14.00, and a low estimate of $4.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 28.72%. 
<img src="https://www.benzinga.com/files/images/story/2025/1739368825_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Sage Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$6.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sage Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Sage Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Sage Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Sage Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SAGE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sage Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Sage Therapeutics</h2>
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
<h3>Understanding the Numbers: Sage Therapeutics's Finances</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Sage Therapeutics showcased positive performance, achieving a revenue growth rate of 337.08% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Sage Therapeutics's net margin excels beyond industry benchmarks, reaching -788.06%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Sage Therapeutics's ROE excels beyond industry benchmarks, reaching -15.86%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Sage Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -14.18%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Sage Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Sage Therapeutics Through 7 Analysts

Canaccord Genuity analyst Sumant Kulkarni maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold and lowers the price target from $9 to $8.

Canaccord Genuity Maintains Hold on Sage Therapeutics, Lowers Price Target to $8

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and lowers the price target from $14 to $12.

HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Lowers Price Target to $12

Sage Therapeutics Q4 2024 GAAP EPS $(1.56) Misses $(1.43) Estimate, Sales $12.815M Miss $14.441M Estimate

Biotech giant Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) is scheduled to report fourth-quarter earnings on 12 February.
The Wall Street forecasts fourth-quarter adjusted EPS of $3.35 and sales of $2.40 billion, while fiscal year 2024 adjusted EPS is expected to be $16.34 and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">sales of $9.64 billion</a>.
January 2025 had been an eventful month for Biogen. Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) announced that its Board of Directors initiated a process to explore strategic alternatives and rejected the unsolicited, nonbinding proposal it received from Biogen for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43232552/sage-therapeutics-board-of-directors-initiates-review-of-strategic-alternatives-and-rejects-biogen" rel="noreferrer noopener">$7.22 per share</a>.
In January, the FDA approved the Supplemental marketing application for lecanemab-irmb (Leqembi) intravenous (IV) maintenance dosing once <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43219641/fda-approves-leqembi-lecanemab-irmb-iv-maintenance-dosing-for-the-treatment-of-early-alzheimers-di" rel="noreferrer noopener">every four weeks</a>.
Leqembi is indicated for Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease. After 18 months of once every two weeks initiation phase, a transition to the maintenance dosing regimen of 10 mg/kg once every four weeks may be considered or the regimen of 10 mg/kg once every two weeks may be continued.
The FDA and the European Medicines Agency accepted to review supplemental marketing applications seeking approval for a higher dose regimen of nusinersen for spinal muscular atrophy (SMA).
The higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and a higher maintenance regimen, 28 mg, every 4 months, compared to the approved <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43156759/fda-and-ema-accept-applications-for-higher-dose-regimen-of-nusinersen-in-sma" rel="noreferrer noopener">nusinersen regimen (Spinraza)</a>.&nbsp;
The European Commission asked the CHMP to consider information on the safety of lecanemab that became available after the adoption of the CHMP opinion in November 2024, whether this may require an update of the opinion, and whether the wording of the risk minimization measures in the opinion is clear enough to ensure correct implementation. These will be discussed at the CHMP <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43380334/update-on-regulatory-review-of-lecanemab-for-early-alzheimers-disease-in-the-european-union" rel="noreferrer noopener">meeting in February 2025</a>.
Investors are focused on Biogen's growth strategies. This includes expanding its pipeline, pursuing external business development, or leveraging new opportunities to counter declining revenue in the latter&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say" rel="noreferrer noopener">half of the decade</a>.
In December, Jefferies&nbsp;downgraded&nbsp;Biogen, citing the&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42397286/biogen-downgraded-on-pipeline-setbacks-and-leqembi-sales-slowdown" rel="noreferrer noopener">company's tough setup</a>.
Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030.
Challenges like PET scan reimbursement, slow protocol updates at major hospital networks, and identifying eligible patients continue to hinder adoption.
Price Action: BIIB stock is down 2.61% at $138.81 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/02/43633084/communications-firm-anterix-initiates-strategic-review-with-morgan-stanley-stock-surges" target="_blank" rel="noreferrer noopener">Communications Firm Anterix Initiates Strategic Review With Morgan Stanley, Stock Surges</a></li>
</ul>

Biotech

Large Cap

Health Care

Previews

BIIB

What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday?

<h3>Companies Reporting Before The Bell</h3>
• Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) is estimated to report quarterly earnings at $1.05 per share on revenue of $743.60 million. 
• AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) is likely to report quarterly earnings at $4.26 per share on revenue of $6.81 billion. 
• Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) is estimated to report quarterly loss at $2.12 per share on revenue of $28.84 billion. 
• Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) is projected to report quarterly earnings at $0.48 per share on revenue of $5.20 billion. 
• DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) is projected to report quarterly earnings at $0.98 per share on revenue of $3.07 billion. 
• BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $45.65 billion. 
• Yatra Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTRA#NASDAQ">YTRA</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $15.02 million. 
• NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) is estimated to report quarterly earnings at $0.82 per share on revenue of $217.60 million. 
• OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) is projected to report quarterly loss at $0.03 per share on revenue of $48.93 million. 
• Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) is estimated to report quarterly loss at $1.04 per share on revenue of $59.49 million. 
• Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) is expected to report quarterly loss at $0.01 per share on revenue of $26.52 million. 
• Jerash Holdings (US) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRSH#NASDAQ">JRSH</a>) is expected to report quarterly loss at $0.01 per share on revenue of $37.65 million. 
• Ceragon Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNT#NASDAQ">CRNT</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $105.16 million. 
• SolarWinds (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $202.91 million. 
• Curbline Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURB#NYSE">CURB</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $28.88 million. 
• IPG Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPGP#NASDAQ">IPGP</a>) is projected to report quarterly earnings at $0.22 per share on revenue of $229.47 million. 
• LCI Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCII#NYSE">LCII</a>) is projected to report quarterly earnings at $0.31 per share on revenue of $799.81 million. 
• Sequans Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) is likely to report quarterly loss at $0.07 per share on revenue of $10.50 million. 
• Sunoco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUN#NYSE">SUN</a>) is likely to report quarterly earnings at $1.34 per share on revenue of $5.92 billion. 
• WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $650.00 million. 
• Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) is projected to report quarterly earnings at $1.36 per share on revenue of $2.63 billion. 
• Marriott Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) is likely to report quarterly earnings at $2.36 per share on revenue of $6.39 billion. 
• MYT Netherlands Parent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYTE#NYSE">MYTE</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $217.77 million. 
• Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) is projected to report quarterly earnings at $0.43 per share on revenue of $2.73 billion. 
• WESCO Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>) is expected to report quarterly earnings at $3.23 per share on revenue of $5.42 billion. 
• TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $463.18 million. 
• USA Compression Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USAC#NYSE">USAC</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $242.95 million. 
• S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) is projected to report quarterly earnings at $3.41 per share on revenue of $3.46 billion. 
• Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $10.70 billion. 
• Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) is projected to report quarterly earnings at $2.27 per share on revenue of $4.13 billion. 
• Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) is estimated to report quarterly earnings at $0.87 per share on revenue of $1.84 billion. 
• GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $1.83 billion. 
• Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) is expected to report quarterly earnings at $1.81 per share on revenue of $4.03 billion. 
<h3>Companies Reporting After The Bell</h3>
• Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is likely to report quarterly earnings at $1.70 per share on revenue of $7.15 billion. 
• Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) is projected to report quarterly earnings at $1.06 per share on revenue of $129.03 million. 
• Avis Budget Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) is projected to report quarterly loss at $1.03 per share on revenue of $2.73 billion. 
• Franklin Street Props (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FSP#AMEX">FSP</a>) is projected to report quarterly loss at $0.07 per share on revenue of $30.83 million. 
• Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) is projected to report quarterly earnings at $0.55 per share on revenue of $1.49 billion. 
• Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) is projected to report quarterly earnings at $0.63 per share on revenue of $5.78 billion. 
• Evolution Petroleum (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EPM#AMEX">EPM</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $22.73 million. 
• Bioceres Crop Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOX#NASDAQ">BIOX</a>) is expected to report quarterly earnings at $0.15 per share on revenue of $144.62 million. 
• Genasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNSS#NASDAQ">GNSS</a>) is projected to report quarterly loss at $0.16 per share on revenue of $6.59 million. 
• Everus Construction Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECG#NYSE">ECG</a>) is expected to report earnings for its fourth quarter. 
• United Fire Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFCS#NASDAQ">UFCS</a>) is likely to report quarterly earnings at $0.66 per share on revenue of $327.70 million. 
• Tigo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYGO#NASDAQ">TYGO</a>) is estimated to report quarterly loss at $0.16 per share on revenue of $15.62 million. 
• HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $28.48 million. 
• Atomera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOM#NASDAQ">ATOM</a>) is likely to report quarterly loss at $0.14 per share on revenue of $500 thousand. 
• Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) is projected to report quarterly loss at $1.38 per share on revenue of $14.11 million. 
• Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) is expected to report quarterly earnings at $0.48 per share on revenue of $562.72 million. 
• Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) is projected to report quarterly earnings at $0.34 per share on revenue of $106.25 million. 
• BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) is projected to report quarterly earnings at $0.50 per share on revenue of $168.10 million. 
• Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) is likely to report quarterly earnings at $4.90 per share on revenue of $766.63 million. 
• Allison Transmission (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) is likely to report quarterly earnings at $1.91 per share on revenue of $765.40 million. 
• Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $15.30 million. 
• W.P. Carey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>) is estimated to report quarterly earnings at $1.20 per share on revenue of $397.32 million. 
• Sensata Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) is estimated to report quarterly earnings at $0.75 per share on revenue of $883.43 million. 
• Pitney Bowes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $509.65 million. 
• America Movil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>) is expected to report quarterly earnings at $0.38 per share on revenue of $12.27 billion. 
• Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>) is expected to report quarterly earnings at $1.02 per share on revenue of $3.13 billion. 
• Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) is expected to report quarterly loss at $0.24 per share on revenue of $45.84 million. 
• Anterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEX#NASDAQ">ATEX</a>) is expected to report quarterly loss at $0.61 per share on revenue of $1.88 million. 
• IAC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) is likely to report quarterly earnings at $0.39 per share on revenue of $934.31 million. 
• Mercury General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>) is estimated to report quarterly earnings at $0.64 per share on revenue of $1.23 billion. 
• American Intl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) is expected to report quarterly earnings at $1.53 per share on revenue of $6.70 billion. 
• Diodes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIOD#NASDAQ">DIOD</a>) is estimated to report quarterly earnings at $0.32 per share on revenue of $337.10 million. 
• Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) is projected to report quarterly loss at $0.01 per share on revenue of $1.55 billion. 
• Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $532.04 million. 
• Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $533.26 million. 
• Teradata (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) is projected to report quarterly earnings at $0.44 per share on revenue of $417.67 million. 
• DoubleDown Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) is projected to report quarterly earnings at $0.58 per share on revenue of $85.54 million. 
• Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $65.48 million. 
• OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $128.13 million. 
• MRC Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $726.90 million. 
• Mirion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MIR#NYSE">MIR</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $245.02 million. 
• Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $181.92 million. 
• Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) is projected to report quarterly earnings at $1.12 per share on revenue of $2.12 billion. 
• Silvercorp Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SVM#AMEX">SVM</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $80.90 million. 
• Kite Realty Gr Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRG#NYSE">KRG</a>) is projected to report quarterly earnings at $0.53 per share on revenue of $209.12 million. 
• Gladstone Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLAD#NASDAQ">GLAD</a>) is likely to report quarterly earnings at $0.53 per share on revenue of $24.40 million. 
• InvenTrust Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVT#NYSE">IVT</a>) is likely to report quarterly earnings at $0.41 per share on revenue of $71.16 million. 
• Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $254.21 million. 
• Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) is projected to report quarterly earnings at $0.38 per share on revenue of $21.43 million. 
• Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $491.36 million. 
• Assurant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>) is likely to report quarterly earnings at $3.51 per share on revenue of $3.08 billion. 
• Acadia Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKR#NYSE">AKR</a>) is likely to report quarterly earnings at $0.33 per share on revenue of $83.33 million. 
• Brighthouse Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) is estimated to report quarterly earnings at $4.58 per share on revenue of $2.22 billion. 
• Highwoods Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIW#NYSE">HIW</a>) is projected to report quarterly earnings at $0.86 per share on revenue of $203.87 million. 
• Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $189.30 million. 
• DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) is projected to report quarterly earnings at $0.33 per share on revenue of $2.84 billion. 
• Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) is projected to report quarterly earnings at $1.03 per share on revenue of $156.13 million. 
• Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $256.84 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Sage Therapeutics

ニュース

最新ニュース Sage Therapeutics (NASDAQ:SAGE) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル